AMH and hyperandrogenism: In the present study, PCOS phenotypes and dyslipidemia were observed in animals that received letrozole, which were confirmed by increased testosterone (hyperandrogenism) and AMH levels, 17-β estradiol depletion and impaired androgen clearance (SHBG) with multiple ovarian cysts, as well as disrupted lipid profile compared with control animals.